BioXcel Therapeutics, Inc. Common Stock (BTAI) is a publicly traded Healthcare sector company. As of May 21, 2026, BTAI trades at $1.07 with a market cap of $30.59M and a P/E ratio of -0.24. BTAI moved +1.39% today. Year to date, BTAI is -39.11%; over the trailing twelve months it is -23.24%. Its 52-week range spans $1.01 to $13.28. Analyst consensus is buy with an average price target of $7.67. Rallies surfaces BTAI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
BTAI financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. BTAI recently traded at $1.07. Market cap is $30.59M. P/E ratio is -0.24. Revenue is $680.00K.
| Metric | Value |
|---|---|
| Price | $1.07 |
| Market Cap | $30.59M |
| P/E Ratio | -0.24 |
| EPS | $-4.52 |
| Dividend Yield | 0.00% |
| 52-Week High | $13.28 |
| 52-Week Low | $1.01 |
| Volume | 5.42K |
| Avg Volume | 0 |
| Revenue (TTM) | $680.00K |
| Net Income | $-75.33M |
| Gross Margin | 36.32% |
| Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $642.00K | $-69.90M | $-5.73 |
| 2024 | $2.27M | $-59.60M | $-23.51 |
| 2023 | $1.38M | $-179.05M | $-6.15 |
| 2022 | $375.00K | $-165.76M | $-5.92 |
3 analysts cover BTAI: 0 strong buy, 2 buy, 0 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $7.67.